Moreover, the combination of SGC0946 and GSK343 significantly reduced tumour growth in comparison to single agent therapy, suggesting combined inhibition of EZH2 and DOT1L may represent an effective therapeutic approach for NB patients. The gene discussed is DOT1L; the disease is neuroblastoma.